NYSE$OSCR

Oscar Health Inc · Q4 2024 earnings

Q4 2024 earnings · · After market close · Investor relations

Briefing

Oscar Health reported positive full year results and achieved profitability for the first time.

Oscar Health announced its Q4 and full year 2024 results, reporting positive Adjusted EBITDA and net income profitability for the first time in company history. The company's revenue reached $9.2 billion for the year, driven by membership growth and strong retention.

  • Reported both Adjusted EBITDA and net income profitability.
  • Achieved all-time-high membership.
  • Demonstrated ability to deliver sustained profitable growth.
  • Total Revenue for 2024 was $9.2 billion, a 56.5% increase year-over-year.

Headline financials

Total Revenue

$2.39B

Previous: $1.43B+67.1%
EPS (adj)

-$0.62

Previous: -$0.66+6.1%
Capital Expenditures

-$6.82M

Previous: -$6.1M-11.8%
Free Cash Flow

$340M

Previous: $291M+16.9%
Net Income

-$154M

Previous: -$150M-2.5%
Operating Income

-$148M

Previous: -$145M-1.5%

Revenue & EPS history

Oscar Health · Revenue · Quarterly

$2.39B

Q4 2024+67.1%vs Q4 2023
Beat estimate in 5 of 15 quarters(33%)
ActualEstimate

Forward guidance

The Company is introducing its outlook for 2025 including a new metric, Earnings from Operations. For 2025, the Company anticipates Total Revenue of $11.2 billion to $11.3 billion, a Medical Loss Ratio of 80.7% to 81.7%, a SG&A Expense Ratio of 17.6% to 18.1%, and Earnings from Operations of $225 million to $275 million.

Tailwinds

  • Total Revenue of $11.2 billion to $11.3 billion
  • Medical Loss Ratio of 80.7% to 81.7%
  • SG&A Expense Ratio of 17.6% to 18.1%
  • Earnings from Operations of $225 million to $275 million

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+3.7%

Avg return

Earnings day

+5.6%

Avg return

5 days after

+7.5%

Avg return

30 days after

64%

16 / 25 earnings

Positive

+30.0%

Q1 2025

Best reaction

-23.9%

Q3 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+2.7%+22.6%+36.6%
Q4 2025+1.7%+6.0%+2.7%
Q3 2025-2.8%-12.8%-1.5%
Q1 2025+30.0%+28.7%+18.0%
Q4 2024+3.1%-3.7%+4.5%
Q3 2024-12.9%-12.8%+0.4%
Q2 2024+7.2%+4.4%-1.4%
Q1 2024+9.3%+14.1%+2.8%
Q4 2023+22.7%+27.5%+7.7%
Q3 2023+23.5%+24.5%+42.0%
Q2 2023+8.6%+1.9%-10.5%
Q1 2023-8.8%-6.6%+17.8%
Q4 2022+21.0%+36.2%-3.9%
Q3 2022-23.9%-4.5%-11.3%
Q2 2022+19.9%+21.1%-3.7%
Q1 2022-8.9%-2.0%-25.0%
Q4 2019+6.3%+2.5%+39.1%
Q4 2021+2.4%+15.6%+21.9%
Q3 2020-2.4%-6.3%-12.7%
Q3 2021-23.3%-25.2%-33.0%
Q2 2020-16.4%-11.8%+19.4%
Q2 2021-0.9%-12.0%+17.9%
Q4 2020+15.2%+14.5%+23.1%
Q1 2020+15.2%+14.5%+23.1%
Q1 2021+3.6%+4.2%+14.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro